Stockreport

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglo [Read more]